The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naive Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification

被引：12
|
作者：
Passamonti, Francesco [1 ,2 ]
Foran, James M. [3 ,4 ]
Tandra, Anand [5 ]
De Stefano, Valerio [6 ,7 ]
Fox, Maria Laura [8 ]
Mattour, Ahmad H. [9 ]
McMullin, Mary Frances [10 ]
Perkins, Andrew Charles [11 ]
Rodriguez-Macias, Gabriela [12 ]
Sibai, Hassan [13 ]
Qin, Qin [14 ]
Sun, Yan [14 ]
Potluri, Jalaja [14 ]
Harb, Jason [14 ]
How, Jonathan [15 ]
机构：
[1] Univ Insubria, Univ Hosp Osped Circolo, Div Hematol, Varese, Italy
[2] Univ Insubria, Fdn Macchi ASST Sette Laghi, Varese, Italy
[3] Mayo Clin, Div Hematol Oncol, Jacksonville, FL 32224 USA
[4] Mayo Clin, Blood & Marrow Transplanat & Cellular Therapy, Jacksonville, FL 32224 USA
[5] Indiana Blood & Marrow Transplant, Indianapolis, IN USA
[6] Catholic Univ, Sect Hematol, Dept Radiol & Hematol Sci, Fdn Policlin A Gemelli, Rome, Italy
[7] Fdn Policlin Univ Agostino Gemelli IRCC, Rome, Italy
[8] Univ Hosp Vall dHebron Barcelona, Dept Hematol Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[9] Henry Ford Hosp, Detroit, MI 48202 USA
[10] Queens Univ, Ctr Med Educ, Belfast, Antrim, North Ireland
[11] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic, Australia
[12] Gregorio Maranon Gen Univ Hosp HGUGM, Dept Hematol, Madrid, Spain
[13] Univ Hlth Network, Div Med Oncol & Hematol, Leukemia Program, Princess Margaret Canc Ctr, Toronto, ON, Canada
[14] AbbVie Inc, N Chicago, IL USA
[15] McGill Univ, Montreal, PQ, Canada
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-157949
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Addition of navitoclax to ruxolitinib mediates responses suggestive of disease modification in patients with myelofibrosis previously treated with ruxolitinib monotherapy.
    Pemmaraju, Naveen
    Garcia, Jacqueline
    Potluri, Jalaja
    Sun, Yan
    Harb, Jason
    Tantravahi, Srinivas K.
    Verstovsek, Srdan
    Harrison, Claire
    CANCER RESEARCH, 2022, 82 (12)
  • [2] Navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study.
    Passamonti, Francesco
    Foran, James M.
    Tandra, Anand
    De Stefano, Valerio
    Fox, Maria Laura
    Mattour, Ahmad Hatem
    McMullin, Mary Frances
    Perkins, Andrew
    Rodriguez-Macias, Gabriela
    Sibai, Hassan
    Qin, Qin Q.
    Potluri, Jalaja
    How, Jonathan B.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
    Rampal, Raajit K.
    Grosicki, Sebastian
    Chraniuk, Dominik
    Abruzzese, Elisabetta
    Bose, Prithviraj
    Gerds, Aaron T.
    Vannucchi, Alessandro M.
    Palandri, Francesca
    Lee, Sung-Eun
    Gupta, Vikas
    Lucchesi, Alessandro
    Oh, Stephen T.
    Kuykendall, Andrew T.
    Patriarca, Andrea
    alvarez-Larran, Alberto
    Mesa, Ruben
    Kiladjian, Jean-Jacques
    Talpaz, Moshe
    Scandura, Joseph M.
    Lavie, David
    Harris, Morgan
    Kays, Sarah-Katharina
    Li, Qing
    Boxhammer, Rainer
    Brown, Barbara
    Jegg, Anna-Maria
    Harrison, Claire N.
    Mascarenhas, John
    NATURE MEDICINE, 2025,
  • [4] Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naive Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification
    Tantravahi, Srinivas K.
    Kishtagari, Ashwin
    Maher, Keri
    Mohan, Sanjay
    Prchal, Josef T.
    Wang, Xulong
    Chamoun, Kamal
    Walker, Christopher J.
    Taverna, Pietro
    Ali, Haris
    BLOOD, 2023, 142
  • [5] Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naive Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study
    Mascarenhas, John
    Rampal, Raajit K.
    Grosicki, Sebastian
    Chraniuk, Dominik
    Abruzzese, Elisabetta
    Bose, Prithviraj
    Gerds, Aaron
    Vannucchi, Alessandro M.
    Palandri, Francesca
    Lee, Sung-Eun
    Gupta, Vikas
    Lucchesi, Alessandro
    Oh, Stephen T.
    Kuykendall, Andrew T.
    Patriarca, Andrea
    Alvarez-Larran, Alberto
    Mesa, Ruben
    Kiladjian, Jean-Jacques
    Talpaz, Moshe
    Lavie, David
    Harris, Morgan
    Kays, Sarah-Katharina
    Jegg, Anna Maria
    Wu, Manlei
    Brown, Barbara
    Harrison, Claire
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S416 - S417
  • [6] CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) PROTEIN INHIBITOR, IN COMBINATION WITH RUXOLITINIB, IN JAK INHIBITOR-NAIVE MYELOFIBROSIS PATIENTS: UPDATE OF MANIFEST PHASE 2 STUDY
    Palandri, F.
    Mascarenhas, J.
    Harrison, C.
    Patriarca, A.
    Devos, T.
    Rampal, R.
    Vannucchi, A.
    Passamonti, F.
    Mead, A.
    Kremyanskaya, M.
    Somervaille, T.
    Wondergem, M.
    Hoffman, R.
    Luptakova, K.
    Wang, J.
    Colak, G.
    Shao, J.
    Bobba, S.
    Trojer, P.
    Verstovsek, S.
    Gupta, V.
    HAEMATOLOGICA, 2021, 106 (10) : 5 - 6
  • [7] BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis - JAK Inhibitor-Naive or With Suboptimal Response to Ruxolitinib - Preliminary Data From the MANIFEST Study
    Mascarenhas, John
    Kremyanskaya, Marina
    Patriarca, Andrea
    Harrison, Claire
    Bose, Prithviraj
    Rampal, Raajit K.
    Palandri, Francesca
    Devos, Timothy
    Passamonti, Francesco
    Hobbs, Gabriela
    Talpaz, Moshe
    Vannucchi, Alessandro
    Kiladjian, Jean-Jacques
    Verstovsek, Srdan
    Hoffman, Ron
    Salama, Mohamed E.
    Chen, Dong
    Taverna, Pietro
    Chang, Alex
    Colak, Gozde
    Klein, Sandra
    Gupta, Vikas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S335 - S336
  • [8] Pelabresib Plus Ruxolitinib Combination Therapy in JAK Inhibitor-Naive Patients With Myelofibrosis in the Phase 3 MANIFEST-2 Study: Preliminary Evidence of Bone Marrow Recovery
    Mascarenhas, John
    Rampal, Raajit K.
    Vannucchi, Alessandro M.
    Gupta, Vikas
    Oh, Stephen T.
    Kuykendall, Andrew T.
    Mesa, Ruben
    Kiladjian, Jean-Jacques
    Talpaz, Moshe
    Kremyanskaya, Marina
    Scandura, Joseph
    Kraeft, Tabea
    Eliane, Jean-Pierre
    Chang, Tzuu-Wang
    Cui, Jike
    Kuffer, Christian
    Boxhammer, Rainer
    Harrison, Claire
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S417 - S418
  • [9] Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis: A Phase 2 Study
    Harrison, Claire
    Garcia, Jacqueline S.
    Mesa, Ruben
    Somervaille, Tim
    Ritchie, Ellen K.
    Komrokji, Rami S.
    Pemmaraju, Naveen
    Jamieson, Catriona
    Papadantonakis, Nikolaos
    Foran, James M.
    O'Connell, Casey L.
    Verstovsek, Srdan
    Jung, Paul
    Holes, Leanne
    Masud, Abdullah
    Harb, Jason
    Hutti, Jessica E.
    Prchal, Josef T.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S325 - S325
  • [10] Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naive Patients with Myelofibrosis
    Mascarenhas, John O.
    Grosicki, Sebastian
    Chraniuk, Dominik
    Abruzzese, Elisabetta
    Bose, Prithviraj
    Gerds, Aaron T.
    Vannucchi, Alessandro M.
    Palandri, Francesca
    Lee, Sung-Eun
    Gupta, Vikas
    Lucchesi, Alessandro
    Oh, Stephen
    Kuykendall, Andrew T.
    Patriarca, Andrea
    Alvarez-Larran, Alberto
    Mesa, Ruben
    Kiladjian, Jean-Jacques
    Talpaz, Moshe
    Harris, Morgan
    Kays, Sarah-Katharina
    Li, Qing
    Brown, Barbara
    Jegg, Anna-Maria
    Harrison, Claire
    Rampal, Raajit
    BLOOD, 2024, 144 : 3178 - 3180
12345